Belzutifan is under clinical development by Merck and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Belzutifan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belzutifan (Welireg), is an inhibitor of hypoxia-inducible factor-2α (HIF-2α). It is formulated as film coated tablets, coated tablets for oral route of administration. Welireg is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
MK-6482 (PT-2977) is under development for the treatment of clear cell renal cell carcinoma (ccRCC), gastrointestinal stromal tumor (GIST), von Hippel-Lindau disease-associated renal cell carcinoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, endometrial cancer, esophageal squamous cell carcinoma, colorectal cancer, bile duct cancer (cholangiocarcinoma), gallbladder cancer, clear cell renal cell carcinoma, metastatic renal cell carcinoma, advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), recurrent glioblastoma multiforme and rare cancers. It is a small molecule. It is administered through oral route. The drug candidate targets hypoxia-inducible factor-2 alpha (HIF-2alpha). It was also under development for the treatment of iron overload (hemosiderosis) and pulmonary arterial hypertension.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Belzutifan’s drug-specific PTSR and LoA scores, buy the report here.